3 results
Primary objectives:To assess the bioequivalence of a single-dose TRI as a whole tablet (reference) compared to a crushed and suspended tablet (intervention I).To assess the bioequivalence of a single-dose TRI as a whole tablet (reference) compared…
Lu AF28996 is an orally administered investigational compound of a potent, long-acting dopamine agonist, Lu AA40326, currently under development by H. Lundbeck A/S for the treatment of Parkinson*s disease (PD). Primary Objective:to investigate the…
Primary objectives-To assess the concordance between [68Ga]Ga-PentixaFor PET/CT and AVS for identification and/or lateralization of APAs in patients with PA. (Step 1) -To assess non-inferiority in terms of clinical outcomes of [68Ga]Ga-PentixaFor…